Eckert & Ziegler SE

🎉 We're celebrating a 𝘆𝗲𝗮𝗿 𝗳𝘂𝗹𝗹 𝗼𝗳 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀 and are looking ahead to a 𝗯𝗿𝗶𝗴𝗵𝘁 𝗳𝘂𝘁𝘂𝗿𝗲 🌟 As we close the chapter on an 𝗲𝘅𝗰𝗲𝗽𝘁𝗶𝗼𝗻𝗮𝗹 𝘆𝗲𝗮𝗿, Dr. Harald Hasselmann, our CEO shares a 𝘀𝗽𝗲𝗰𝗶𝗮𝗹  𝗺𝗲𝘀𝘀𝗮𝗴𝗲 𝗳𝗼𝗿 𝗼𝘂𝗿 𝘃𝗮𝗹𝘂𝗲𝗱 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝘁𝘆. 🎥 🎄 With the holiday season upon us, we want to take a moment to express our 𝗱𝗲𝗲𝗽 𝗴𝗿𝗮𝘁𝗶𝘁𝘂𝗱𝗲 𝗳𝗼𝗿 𝘆𝗼𝘂𝗿 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲𝗱 𝘁𝗿𝘂𝘀𝘁 𝗮𝗻𝗱 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻. Your support fuels our mission to 𝗺𝗮𝗸𝗲 𝗮 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝗰𝗲 in nuclear medicine, radiation therapy and isotope production. ⚛️ 🥂Here's to a New Year filled with 𝗴𝗿𝗼𝘄𝘁𝗵, 𝘀𝗵𝗮𝗿𝗲𝗱 𝗮𝗰𝗵𝗶𝗲𝘃𝗲𝗺𝗲𝗻𝘁𝘀, 𝗮𝗻𝗱 𝗲𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀! 𝗧𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 for being part of this exciting journey. 👏 #SeasonsGreetings #NewYear #ThankYou #ContributingToSavingLives  

👉 𝗔𝗿𝗯𝗲𝗶𝘁𝗲𝗻 𝗯𝗲𝗶 𝗘𝗰𝗸𝗲𝗿𝘁 & 𝗭𝗶𝗲𝗴𝗹𝗲𝗿: 𝗩𝗼𝗿𝘁𝗲𝗶𝗹𝗲, 𝗱𝗶𝗲 𝗯𝗲𝘄𝗲𝗴𝗲𝗻! 🚇 Letzte Woche hatten wir Besuch von einem Team der Berliner Verkehrsbetriebe (BVG), das unsere Mitarbeiter:innen über das 𝗝𝗼𝗯𝘁𝗶𝗰𝗸𝗲𝘁-𝗔𝗻𝗴𝗲𝗯𝗼𝘁 informierte. 💡 🚍 Dank der Zusammenarbeit mit der BVG profitieren unsere Kolleg:innen von: ✅ 𝗔𝗿𝗯𝗲𝗶𝘁𝗴𝗲𝗯𝗲𝗿𝘇𝘂𝘀𝗰𝗵𝘂̈𝘀𝘀𝗲𝗻 𝘇𝘂𝗿 𝗺𝗼𝗻𝗮𝘁𝗹𝗶𝗰𝗵𝗲𝗻 𝗧𝗶𝗰𝗸𝗲𝘁𝗴𝗲𝗯𝘂̈𝗵𝗿 und ✅ 𝗥𝗮𝗯𝗮𝘁𝘁𝗲𝗻 𝗮𝘂𝗳 𝗱𝗲𝗻 𝗿𝗲𝗴𝘂𝗹𝗮̈𝗿𝗲𝗻 𝗧𝗶𝗰𝗸𝗲𝘁𝗽𝗿𝗲𝗶𝘀 𝗱𝘂𝗿𝗰𝗵 𝗱𝗶𝗲 𝗕𝗩𝗚 Dadurch möchten wir unserem Team nicht nur den 𝗔𝗿𝗯𝗲𝗶𝘁𝘀𝘄𝗲𝗴 𝗲𝗿𝗹𝗲𝗶𝗰𝗵𝘁𝗲𝗿𝗻, sondern auch einen 𝗕𝗲𝗶𝘁𝗿𝗮𝗴 𝘇𝘂𝗿 𝗙𝗼̈𝗿𝗱𝗲𝗿𝘂𝗻𝗴 𝗻𝗮𝗰𝗵𝗵𝗮𝗹𝘁𝗶𝗴𝗲𝗿 𝗠𝗼𝗯𝗶𝗹𝗶𝘁𝗮̈𝘁 leisten. Einen 𝗴𝗿𝗼ß𝗲𝗻 𝗗𝗮𝗻𝗸 𝗮𝗻 𝗱𝗶𝗲 𝗕𝗩𝗚 für die Unterstützung, unseren Mitarbeiter:innen dieses Angebot näherzubringen. 💛 Das Jobticket ist nur 𝗲𝗶𝗻𝗲𝗿 𝘃𝗼𝗻 𝘃𝗶𝗲𝗹𝗲𝗻 𝗩𝗼𝗿𝘁𝗲𝗶𝗹𝗲𝗻, die Eckert & Ziegler seinen Mitarbeiter:innen bietet. Egal ob 𝗠𝗼𝗯𝗶𝗹𝗶𝘁𝗮̈𝘁, 𝗪𝗲𝗶𝘁𝗲𝗿𝗲𝗻𝘁𝘄𝗶𝗰𝗸𝗹𝘂𝗻𝗴 𝗼𝗱𝗲𝗿 𝗪𝗼𝗿𝗸-𝗟𝗶𝗳𝗲-𝗕𝗮𝗹𝗮𝗻𝗰𝗲 – wir setzen auf ein 𝗨𝗺𝗳𝗲𝗹𝗱, 𝗶𝗻 𝗱𝗲𝗺 𝘀𝗶𝗰𝗵 𝗷𝗲𝗱𝗲:𝗿 𝗲𝗻𝘁𝗳𝗮𝗹𝘁𝗲𝗻 𝗸𝗮𝗻𝗻. ✨ 👋 𝗠𝗼̈𝗰𝗵𝘁𝗲𝗻 𝗮𝘂𝗰𝗵 𝗦𝗶𝗲 𝗧𝗲𝗶𝗹 𝘂𝗻𝘀𝗲𝗿𝗲𝘀 𝗧𝗲𝗮𝗺𝘀 𝘄𝗲𝗿𝗱𝗲𝗻? Erfahren Sie mehr über Ihre Möglichkeiten bei uns über den 𝗟𝗶𝗻𝗸 𝗶𝗻 𝗱𝗲𝗻 𝗞𝗼𝗺𝗺𝗲𝗻𝘁𝗮𝗿𝗲𝗻 🔽 #Karriere #Benefits #Nachhaltigkeit #Mobilität  #WirHelfenZuHeilen  

🌏 𝗘𝘅𝗽𝗮𝗻𝗱𝗶𝗻𝗴 𝗚𝗹𝗼𝗯𝗮𝗹 𝗥𝗲𝗮𝗰𝗵: 𝗚𝗮𝗹𝗹𝗶𝗮𝗣𝗵𝗮𝗿𝗺® 𝗦𝘂𝗯𝗺𝗶𝘁𝘁𝗲𝗱 𝗳𝗼𝗿 𝗔𝗽𝗽𝗿𝗼𝘃𝗮𝗹 𝗶𝗻 𝗝𝗮𝗽𝗮𝗻! ✅ Eckert & Ziegler has officially 𝘀𝘂𝗯𝗺𝗶𝘁𝘁𝗲𝗱 𝗚𝗮𝗹𝗹𝗶𝗮𝗣𝗵𝗮𝗿𝗺®, our 68Ge/68Ga Radionuclide Generator, for 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹 𝗯𝘆 𝗝𝗮𝗽𝗮𝗻’𝘀 𝗠𝗶𝗻𝗶𝘀𝘁𝗿𝘆 𝗼𝗳 𝗛𝗲𝗮𝗹𝘁𝗵, 𝗟𝗮𝗯𝗼𝘂𝗿 𝗮𝗻𝗱 𝗪𝗲𝗹𝗳𝗮𝗿𝗲 (MHLW). This milestone is set to bring cutting-edge 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝘁𝗼𝗼𝗹𝘀 like 68Ga-PSMA-11 𝗰𝗹𝗼𝘀𝗲𝗿 𝘁𝗼 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗽𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗮𝗹𝘀 𝗮𝗻𝗱 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 in Japan. 𝗔 𝗯𝗶𝗴 𝘁𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 to Novartis Japan (Novartis Pharma K.K.), our trusted partner in managing safety information and 𝗱𝗶𝘀𝘁𝗿𝗶𝗯𝘂𝘁𝗶𝗼𝗻 𝗶𝗻 𝗝𝗮𝗽𝗮𝗻. 🙏 GalliaPharm®, our 𝗚𝗠𝗣-𝗴𝗿𝗮𝗱𝗲 𝗴𝗮𝗹𝗹𝗶𝘂𝗺 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗼𝗿, plays an important role in 𝗽𝗼𝘀𝗶𝘁𝗿𝗼𝗻 𝗲𝗺𝗶𝘀𝘀𝗶𝗼𝗻 𝘁𝗼𝗺𝗼𝗴𝗿𝗮𝗽𝗵𝘆 (𝗣𝗘𝗧) 𝗶𝗺𝗮𝗴𝗶𝗻𝗴, particularly in oncology for 𝗽𝗿𝗼𝘀𝘁𝗮𝘁𝗲 𝗰𝗮𝗻𝗰𝗲𝗿 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝘀 using PSMA imaging. With approval in Japan, we aim to 𝗲𝗺𝗽𝗼𝘄𝗲𝗿 𝘁𝗵𝗲 𝗹𝗼𝗰𝗮𝗹 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝘁𝘆 with reliable tools to 𝗮𝗱𝘃𝗮𝗻𝗰𝗲 𝗲𝗮𝗿𝗹𝘆 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗱𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 and improve patient outcomes. 💙 💬 𝗗𝗿. Deljana Werner, Head of QA and Regulatory Affairs, shared: “As a company 𝗰𝗼𝗺𝗺𝗶𝘁𝘁𝗲𝗱 𝘁𝗼 𝗮𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗻𝘂𝗰𝗹𝗲𝗮𝗿 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗴𝗹𝗼𝗯𝗮𝗹𝗹𝘆, GalliaPharm®’s entry into the Japanese market represents a pivotal opportunity to 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗽𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗮𝗹𝘀 𝗶𝗻 𝗲𝗻𝗵𝗮𝗻𝗰𝗶𝗻𝗴 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗰𝗮𝗿𝗲 through precise and innovative imaging solutions.” This submission underscores Eckert & Ziegler SE’s dedication to 𝘀𝘂𝗽𝗽𝗼𝗿𝘁𝗶𝗻𝗴 𝗱𝗶𝘃𝗲𝗿𝘀𝗲 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗺𝗮𝗿𝗸𝗲𝘁𝘀 and delivering innovative nuclear medicine solutions worldwide. 🔗 For more information, check out the 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗺𝗺𝗲𝗻𝘁𝘀 𝗯𝗲𝗹𝗼𝘄 🔽 #NuclearMedicine #Radiopharmaceuticals #MolecularImaging #ContributingToSavingLives  

📣 𝗘𝗰𝗸𝗲𝗿𝘁 & 𝗭𝗶𝗲𝗴𝗹𝗲𝗿 𝘄𝗶𝗹𝗹 𝘀𝘂𝗽𝗽𝗹𝘆 Ariceum Therapeutics 𝘄𝗶𝘁𝗵 𝗔𝗰-𝟮𝟮𝟱 𝗮𝗻𝗱 𝗟𝘂-𝟭𝟳𝟳 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗼𝗳 𝘁𝗵𝗲𝗶𝗿 𝗻𝗲𝘅𝘁-𝗴𝗲𝗻 𝗿𝗮𝗱𝗶𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 ⚛️ We’re heading into an 𝗲𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 with Ariceum Therapeutics, a biotech innovator in radiopharmaceuticals, to 𝗮𝗱𝘃𝗮𝗻𝗰𝗲 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗰𝗮𝗻𝗰𝗲𝗿 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗳𝗼𝗿 𝗵𝗮𝗿𝗱-𝘁𝗼-𝘁𝗿𝗲𝗮𝘁 𝗰𝗮𝗻𝗰𝗲𝗿𝘀. Under this agreement, 𝗘𝗰𝗸𝗲𝗿𝘁 & 𝗭𝗶𝗲𝗴𝗹𝗲𝗿 𝘄𝗶𝗹𝗹 𝘀𝘂𝗽𝗽𝗹𝘆 non-carrier-added 𝗔𝗰𝘁𝗶𝗻𝗶𝘂𝗺-𝟮𝟮𝟱 (𝗔𝗰-𝟮𝟮𝟱) 𝗮𝗻𝗱 𝗟𝘂𝘁𝗲𝘁𝗶𝘂𝗺-𝟭𝟳𝟳 (𝗟𝘂-𝟭𝟳𝟳) for the radiolabeling of 𝗔𝗿𝗶𝗰𝗲𝘂𝗺’𝘀 𝗹𝗲𝗮𝗱 𝗰𝗮𝗻𝗱𝗶𝗱𝗮𝘁𝗲, 𝘀𝗮𝘁𝗼𝗿𝗲𝗼𝘁𝗶𝗱𝗲. This first-in-class radiopharmaceutical will soon enter clinical development for 𝘀𝗺𝗮𝗹𝗹 𝗰𝗲𝗹𝗹 𝗹𝘂𝗻𝗴 𝗰𝗮𝗻𝗰𝗲𝗿 𝗮𝗻𝗱 𝗠𝗲𝗿𝗸𝗲𝗹 𝗖𝗲𝗹𝗹 𝗖𝗮𝗿𝗰𝗶𝗻𝗼𝗺𝗮. This partnership represents: ✅ A 𝗿𝗲𝗹𝗶𝗮𝗯𝗹𝗲 𝘀𝘂𝗽𝗽𝗹𝘆 of high-quality therapeutic radioisotopes ✅ A major step toward 𝗮𝗱𝗱𝗿𝗲𝘀𝘀𝗶𝗻𝗴 𝗴𝗹𝗼𝗯𝗮𝗹 𝘀𝗵𝗼𝗿𝘁𝗮𝗴𝗲𝘀 of Ac-225 and Lu-177 ✅ 𝗔 𝗯𝗼𝗼𝘀𝘁 𝗳𝗼𝗿 𝗔𝗿𝗶𝗰𝗲𝘂𝗺'𝘀 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀 and future commercialization activities 💬 Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE, highlights: “Both the 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝘀𝘁𝗮𝗿𝘁 𝗳𝗼𝗿 𝗔𝗰-𝟮𝟮𝟱, announced earlier this week, and the 𝘀𝘂𝗰𝗰𝗲𝘀𝘀𝗳𝘂𝗹 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹 𝗼𝗳 𝗧𝗵𝗲𝗿𝗮𝗹𝘂𝗴𝗮𝗻𝗱®, show that our goal is to 𝘀𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗹𝘆 𝗿𝗲𝗱𝘂𝗰𝗲 𝘁𝗵𝗲 𝘀𝗵𝗼𝗿𝘁𝗮𝗴𝗲 of high-quality radioisotopes. We aim to 𝗳𝗼𝘀𝘁𝗲𝗿 𝘁𝗵𝗲 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀 𝗼𝗳 𝗻𝗼𝘃𝗲𝗹 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 in clinical trials and beyond, and thus 𝗰𝗼𝗻𝘁𝗿𝗶𝗯𝘂𝘁𝗲 𝘁𝗼 𝘀𝗮𝘃𝗶𝗻𝗴 𝗹𝗶𝘃𝗲𝘀.” 💬 𝗗𝗿. Manfred Ruediger, CEO of 𝗔𝗿𝗶𝗰𝗲𝘂𝗺 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀, adds: “We are 𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝗳𝗼𝗿𝘄𝗮𝗿𝗱 𝘁𝗼 𝘄𝗼𝗿𝗸𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗘𝗰𝗸𝗲𝗿𝘁 & 𝗭𝗶𝗲𝗴𝗹𝗲𝗿 𝘁𝗲𝗮𝗺 to build a robust supply chain and to 𝗿𝗲𝗹𝗶𝗮𝗯𝗹𝘆 𝗱𝗲𝗹𝗶𝘃𝗲𝗿 𝘁𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝘁𝗵𝗲𝗿𝗮𝗻𝗼𝘀𝘁𝗶𝗰 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 for patients with hard-to-treat cancers.” We’re proud to play a 𝘃𝗶𝘁𝗮𝗹 𝗿𝗼𝗹𝗲 𝗶𝗻 𝗮𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝘁𝗵𝗲𝗿𝗮𝗻𝗼𝘀𝘁𝗶𝗰 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 that may revolutionize cancer care and 𝗶𝗺𝗽𝗿𝗼𝘃𝗲 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀 𝘄𝗼𝗿𝗹𝗱𝘄𝗶𝗱𝗲. 💙 🔗 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 - 𝗟𝗶𝗻𝗸 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗺𝗺𝗲𝗻𝘁𝘀 𝗯𝗲𝗹𝗼𝘄 🔽 #Radiopharmaceuticals #NuclearMedicine #RadioligandTherapy #Theranostics #ContributingToSavingLives  

📣 𝗟𝗲𝗮𝗱𝗲𝗿𝘀𝗵𝗶𝗽 𝗨𝗽𝗱𝗮𝘁𝗲𝘀 𝗮𝘁 𝗘𝗰𝗸𝗲𝗿𝘁 & 𝗭𝗶𝗲𝗴𝗹𝗲𝗿! 👉 Today, we're sharing important changes within our 𝗘𝘅𝗲𝗰𝘂𝘁𝗶𝘃𝗲 𝗮𝗻𝗱 𝗦𝘂𝗽𝗲𝗿𝘃𝗶𝘀𝗼𝗿𝘆 𝗕𝗼𝗮𝗿𝗱𝘀, preparing us for 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲𝗱 𝘀𝘂𝗰𝗰𝗲𝘀𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆 🚀 ▶️ 𝗪𝗲𝗹𝗰𝗼𝗺𝗲 𝗗𝗿. 𝗚𝘂𝗻𝗻𝗮𝗿 𝗠𝗮𝗻𝗻! Starting 𝗝𝗮𝗻𝘂𝗮𝗿𝘆 𝟭, 𝟮𝟬𝟮𝟱, Dr. Gunnar Mann will 𝗷𝗼𝗶𝗻 𝘁𝗵𝗲 𝗘𝘅𝗲𝗰𝘂𝘁𝗶𝘃𝗲 𝗕𝗼𝗮𝗿𝗱, taking on operational responsibility for the 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗦𝗲𝗴𝗺𝗲𝗻𝘁. With 𝗼𝘃𝗲𝗿 𝟮𝟱 𝘆𝗲𝗮𝗿𝘀 𝗮𝘁 𝗘𝗰𝗸𝗲𝗿𝘁 & 𝗭𝗶𝗲𝗴𝗹𝗲𝗿, Dr. Mann brings deep expertise in 𝗿𝗮𝗱𝗶𝗮𝘁𝗶𝗼𝗻 𝗽𝗵𝘆𝘀𝗶𝗰𝘀, 𝗽𝗿𝗼𝗰𝗲𝘀𝘀 𝗺𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁, 𝗮𝗻𝗱 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗽𝗿𝗼𝗷𝗲𝗰𝘁 𝗶𝗺𝗽𝗹𝗲𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻. His leadership will be instrumental in 𝗲𝘅𝗽𝗮𝗻𝗱𝗶𝗻𝗴 𝗼𝘂𝗿 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗰𝗮𝗽𝗮𝗰𝗶𝘁𝘆 𝗮𝗻𝗱 𝗹𝗮𝘂𝗻𝗰𝗵𝗶𝗻𝗴 𝗻𝗲𝘄 𝗳𝗮𝗰𝗶𝗹𝗶𝘁𝗶𝗲𝘀 in this growing segment. 📈 ▶️ 𝗧𝗵𝗮𝗻𝗸 𝗬𝗼𝘂, 𝗝𝘂𝘁𝘁𝗮 𝗟𝘂𝗱𝘄𝗶𝗴! 𝗔𝗳𝘁𝗲𝗿 serving as a member of the 𝗘𝘅𝗲𝗰𝘂𝘁𝗶𝘃𝗲 𝗕𝗼𝗮𝗿𝗱, Jutta Ludwig will 𝘁𝗿𝗮𝗻𝘀𝗶𝘁𝗶𝗼𝗻 𝘁𝗼 𝘁𝗵𝗲 𝗦𝘂𝗽𝗲𝗿𝘃𝗶𝘀𝗼𝗿𝘆 𝗕𝗼𝗮𝗿𝗱 as a delegated member. Her contributions, especially in s𝘁𝗿𝗲𝗻𝗴𝘁𝗵𝗲𝗻𝗶𝗻𝗴 𝗼𝘂𝗿 𝗽𝗼𝘀𝗶𝘁𝗶𝗼𝗻 𝗶𝗻 𝗖𝗵𝗶𝗻𝗮, have been invaluable, and we’re delighted her 𝗲𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲 𝘄𝗶𝗹𝗹 𝗿𝗲𝗺𝗮𝗶𝗻 𝘄𝗶𝘁𝗵 𝘂𝘀. 💡 ▶️ 𝗙𝗮𝗿𝗲𝘄𝗲𝗹𝗹 𝗮𝗻𝗱 𝗧𝗵𝗮𝗻𝗸𝘀 𝘁𝗼 𝗙𝗿𝗮𝗻𝗸 𝗣𝗲𝗿𝘀𝗰𝗵𝗺𝗮𝗻𝗻! 𝗔𝘁 𝘁𝗵𝗲 𝗲𝗻𝗱 𝗼𝗳 𝟮𝟬𝟮𝟰, 𝗙𝗿𝗮𝗻𝗸 𝗣𝗲𝗿𝘀𝗰𝗵𝗺𝗮𝗻𝗻 𝘄𝗶𝗹𝗹 𝗹𝗲𝗮𝘃𝗲 𝘁𝗵𝗲 𝗦𝘂𝗽𝗲𝗿𝘃𝗶𝘀𝗼𝗿𝘆 𝗕𝗼𝗮𝗿𝗱. We thank him for his 𝗺𝗮𝗻𝘆 𝘆𝗲𝗮𝗿𝘀 𝗼𝗳 𝘀𝗲𝗿𝘃𝗶𝗰𝗲 and his 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗰𝗼𝗻𝘁𝗿𝗶𝗯𝘂𝘁𝗶𝗼𝗻𝘀 to the Group's development. 🙏 Under this new leadership, we'll continue our mission of 𝙘𝙤𝙣𝙩𝙧𝙞𝙗𝙪𝙩𝙞𝙣𝙜 𝙩𝙤 𝙨𝙖𝙫𝙞𝙣𝙜 𝙡𝙞𝙫𝙚𝙨 through 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗶𝗺𝗽𝗮𝗰𝘁𝗳𝘂𝗹 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀. 💙 #Leadership #Change #FY2025 #ContributingToSavingLives  

𝗘𝗰𝗸𝗲𝗿𝘁 & 𝗭𝗶𝗲𝗴𝗹𝗲𝗿 𝗕𝗲𝗴𝗶𝗻𝘀 𝗣𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗔𝗰𝘁𝗶𝗻𝗶𝘂𝗺-𝟮𝟮𝟱 🚀 Today, we celebrate the successful c𝗼𝗺𝗺𝗲𝗻𝗰𝗲𝗺𝗲𝗻𝘁 𝗼𝗳 𝗔𝗰𝘁𝗶𝗻𝗶𝘂𝗺-𝟮𝟮𝟱 (𝗔𝗰-𝟮𝟮𝟱) 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 together with our partners at the Nuclear Physics Institute CAS. 🎉 🔬 𝗧𝗵𝗲 𝗜𝗺𝗽𝗮𝗰𝘁 This milestone of our 𝗰𝗼𝗺𝗺𝗼𝗻 𝗽𝗿𝗼𝗷𝗲𝗰𝘁 addresses a 𝗴𝗹𝗼𝗯𝗮𝗹 𝘀𝗵𝗼𝗿𝘁𝗮𝗴𝗲 of this critical radionuclide. Ac-225 is vital for developing 𝗮𝗹𝗽𝗵𝗮-𝗲𝗺𝗶𝘁𝘁𝗶𝗻𝗴 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀, a promising approach in targeted cancer therapies. Our 𝗰𝘆𝗰𝗹𝗼𝘁𝗿𝗼𝗻-𝗯𝗮𝘀𝗲𝗱 production of 𝗔𝗰-𝟮𝟮𝟱 𝗳𝗿𝗼𝗺 𝗥𝗮𝗱𝗶𝘂𝗺-𝟮𝟮𝟲 is a pivotal advancement, ensuring reliability and scalability for 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗮𝗻𝗱 𝗰𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀. 💡 𝗪𝗵𝗮𝘁’𝘀 𝗡𝗲𝘅𝘁? We’ve initiated validation processes for 𝗚𝗠𝗣-𝗴𝗿𝗮𝗱𝗲 𝗔𝗰-𝟮𝟮𝟱, expected to be available in the 𝗳𝗶𝗿𝘀𝘁 𝗵𝗮𝗹𝗳 𝗼𝗳 𝟮𝟬𝟮𝟱. This breakthrough will unlock 𝗻𝗲𝘄 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀 𝗳𝗼𝗿 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 and support the development of potentially 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝘃𝗲 𝗰𝗮𝗻𝗰𝗲𝗿 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀. 🤝 𝗣𝗼𝘄𝗲𝗿𝗲𝗱 𝗯𝘆 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 This achievement was made possible through our 𝘀𝘁𝗿𝗼𝗻𝗴 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗡𝘂𝗰𝗹𝗲𝗮𝗿 𝗣𝗵𝘆𝘀𝗶𝗰𝘀 𝗜𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗖𝘇𝗲𝗰𝗵 𝗔𝗰𝗮𝗱𝗲𝗺𝘆 𝗼𝗳 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 (ÚJF) and the 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗲𝗻𝗴𝗶𝗻𝗲𝗲𝗿𝗶𝗻𝗴 of the team at Eckert & Ziegler Hot Cells. With this success, Eckert & Ziegler continues to 𝗹𝗲𝗮𝗱 𝘁𝗵𝗲 𝘄𝗮𝘆 𝗶𝗻 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻, ensuring a 𝗿𝗲𝗹𝗶𝗮𝗯𝗹𝗲 𝘀𝘂𝗽𝗽𝗹𝘆 𝗼𝗳 𝗶𝘀𝗼𝘁𝗼𝗽𝗲𝘀 for a brighter future in nuclear medicine 🔗 Read the 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 for more details — 𝗟𝗶𝗻𝗸 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗺𝗺𝗲𝗻𝘁𝘀 ⬇️ #Actinium225 #NuclearMedicine #Radiopharmaceuticals #AlphaTherapy #ContributingToSavingLives  

𝗘𝗰𝗸𝗲𝗿𝘁 & 𝗭𝗶𝗲𝗴𝗹𝗲𝗿 𝗮𝘁 𝗗𝗲𝘂𝘁𝘀𝗰𝗵𝗲𝘀 𝗘𝗶𝗴𝗲𝗻𝗸𝗮𝗽𝗶𝘁𝗮𝗹𝗳𝗼𝗿𝘂𝗺 𝟮𝟬𝟮𝟰 ✨ Over the past few days, we participated at one of Europe’s most significant capital market events organized by Deutsche Börse. Under the motto “𝙀𝙣𝙩𝙧𝙚𝙥𝙧𝙚𝙣𝙚𝙪𝙧𝙨 𝙢𝙚𝙚𝙩 𝙞𝙣𝙫𝙚𝙨𝙩𝙤𝙧𝙨,” this forum has been connecting companies and investors since 1996, fostering valuable dialogue and insights into corporate finance. 🏦 𝗢𝘂𝗿 𝗖𝗼𝗻𝘁𝗿𝗶𝗯𝘂𝘁𝗶𝗼𝗻: ▶️ 𝗔𝗻𝗮𝗹𝘆𝘀𝘁𝘀' 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲: Eckert & Ziegler presented its 𝗰𝘂𝗿𝗿𝗲𝗻𝘁 𝗯𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗳𝗶𝗴𝘂𝗿𝗲𝘀 to 𝗮𝗻𝗮𝗹𝘆𝘀𝘁𝘀 𝗮𝗻𝗱 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀 during one of the forum's renowned sessions. ▶️ 𝟭-𝗼𝗻-𝟭 𝗠𝗲𝗲𝘁𝗶𝗻𝗴𝘀: Our 𝗖𝗘𝗢, Dr. Harald Hasselmann, and 𝗛𝗲𝗮𝗱 𝗼𝗳 𝗚𝗿𝗼𝘂𝗽 𝗖𝗼𝗻𝘁𝗿𝗼𝗹𝗹𝗶𝗻𝗴, 𝗝𝘂𝗹𝗶𝗮𝗻 𝗦𝗰𝗵𝗿𝗼̈𝗱𝗲𝗿, held two days of 𝗶𝗻𝘁𝗲𝗻𝘀𝗶𝘃𝗲 𝗱𝗶𝘀𝗰𝘂𝘀𝘀𝗶𝗼𝗻𝘀 𝘄𝗶𝘁𝗵 𝗶𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗶𝗼𝗻𝗮𝗹 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀, sharing insights into our strategy and vision. We are proud to engage in these 𝗶𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁 𝗲𝘅𝗰𝗵𝗮𝗻𝗴𝗲𝘀 that strengthen our relationships with the 𝗳𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝘁𝘆 and support our 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲𝗱 𝗴𝗿𝗼𝘄𝘁𝗵. 📈 𝗔 𝗯𝗶𝗴 𝘁𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 to 𝗗𝗲𝘂𝘁𝘀𝗰𝗵𝗲 𝗕𝗼̈𝗿𝘀𝗲 𝗔𝗚 for hosting such an 𝗼𝘂𝘁𝘀𝘁𝗮𝗻𝗱𝗶𝗻𝗴 𝗲𝘃𝗲𝗻𝘁 and to all the 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀 𝗮𝗻𝗱 𝗮𝗻𝗮𝗹𝘆𝘀𝘁𝘀 who joined us for 𝗺𝗲𝗮𝗻𝗶𝗻𝗴𝗳𝘂𝗹 𝗰𝗼𝗻𝘃𝗲𝗿𝘀𝗮𝘁𝗶𝗼𝗻𝘀! 💬 #CapitalMarkets #InvestorRelations #CorporateFinance #EKF2024 #ContributingToSavingLives  

📣 𝗕𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗡𝗲𝘄𝘀: 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗔𝗽𝗽𝗿𝗼𝘃𝗮𝗹 𝗳𝗼𝗿 𝗧𝗵𝗲𝗿𝗮𝗹𝘂𝗴𝗮𝗻𝗱® - 𝗟𝘂𝘁𝗲𝘁𝗶𝘂𝗺-𝟭𝟳𝟳 𝗖𝗵𝗹𝗼𝗿𝗶𝗱𝗲 (𝗻.𝗰.𝗮) 🙌 Today, Eckert & Ziegler SE's proprietary Theralugand® has 𝗿𝗲𝗰𝗲𝗶𝘃𝗲𝗱 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹 from the 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗖𝗼𝗺𝗺𝗶𝘀𝘀𝗶𝗼𝗻! 🎉 This milestone marks a new era for our non-carrier added Lutetium-177 chloride, which is now 𝗿𝗲𝗮𝗱𝘆 𝗳𝗼𝗿 𝗿𝗼𝘂𝘁𝗶𝗻𝗲 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 across the 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗘𝗰𝗼𝗻𝗼𝗺𝗶𝗰 𝗔𝗿𝗲𝗮 (EEA). 🌍 Theralugand® offers 𝗵𝗶𝗴𝗵-𝗽𝘂𝗿𝗶𝘁𝘆, 𝗚𝗠𝗣-𝗰𝗼𝗺𝗽𝗹𝗶𝗮𝗻𝘁 𝗟𝘂𝘁𝗲𝘁𝗶𝘂𝗺-𝟭𝟳𝟳 designed for the labeling of radiopharmaceuticals, enabling innovative therapies for conditions like neuroendocrine tumors and metastatic prostate cancer. 𝗣𝗿𝗲𝘃𝗶𝗼𝘂𝘀𝗹𝘆 𝗹𝗶𝗺𝗶𝘁𝗲𝗱 𝘁𝗼 𝗶𝗻𝘃𝗲𝘀𝘁𝗶𝗴𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝘂𝘀𝗲, Theralugand® can now support 𝗿𝗼𝘂𝘁𝗶𝗻𝗲 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀. 🏥 Through 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀 𝘄𝗶𝘁𝗵 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗼𝗿𝘀 worldwide, Eckert & Ziegler is advancing targeted radiotherapies, addressing the 𝗴𝗿𝗼𝘄𝗶𝗻𝗴 𝗱𝗲𝗺𝗮𝗻𝗱 for reliable therapeutic radioisotopes. 📈 💬 Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE, shares: “We are excited to achieve the 𝗘𝗖 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹 𝗳𝗼𝗿 𝗧𝗵𝗲𝗿𝗮𝗹𝘂𝗴𝗮𝗻𝗱®, a critical step in making innovative treatment options 𝘄𝗶𝗱𝗲𝗹𝘆 𝗮𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲 𝗳𝗼𝗿 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝗮𝗰𝗿𝗼𝘀𝘀 𝗘𝘂𝗿𝗼𝗽𝗲. This accomplishment reflects our 𝗱𝗲𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝘁𝗼 𝘁𝗵𝗲 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗱𝗶𝘀𝘁𝗿𝗶𝗯𝘂𝘁𝗶𝗼𝗻 𝗼𝗳 𝗿𝗲𝗹𝗶𝗮𝗯𝗹𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀.” We’re 𝗿𝗮𝗺𝗽𝗶𝗻𝗴 𝘂𝗽 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 to ensure a 𝘀𝘁𝗮𝗯𝗹𝗲 𝘀𝘂𝗽𝗽𝗹𝘆 𝗼𝗳 𝗟𝘂𝘁𝗲𝘁𝗶𝘂𝗺-𝟭𝟳𝟳, contributing to the continued evolution of cancer care globally. 🚀 Read the full press release - Link in the comments below ⬇️ #NuclearMedicine #RadioligandTherapy #Radiopharmaceuticals #Lutetium #ContributingToSavingLives  

📣 𝗘𝗰𝗸𝗲𝗿𝘁 & 𝗭𝗶𝗲𝗴𝗹𝗲𝗿 𝗥𝗮𝗶𝘀𝗲𝘀 𝗙𝗼𝗿𝗲𝗰𝗮𝘀𝘁 𝗳𝗼𝗿 𝟮𝟬𝟮𝟰! 📈 Based on our 𝘀𝘁𝗿𝗼𝗻𝗴 𝟵-𝗺𝗼𝗻𝘁𝗵 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 and 𝗽𝗼𝘀𝗶𝘁𝗶𝘃𝗲 𝗯𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗼𝘂𝘁𝗹𝗼𝗼𝗸 for Q4, our Executive Board has 𝗿𝗮𝗶𝘀𝗲𝗱 𝘁𝗵𝗲 𝗮𝗻𝗻𝘂𝗮𝗹 𝗳𝗼𝗿𝗲𝗰𝗮𝘀𝘁 for 2024 🙌 ▶️ 𝗦𝗮𝗹𝗲𝘀: Now expected at ~𝗘𝗨𝗥 𝟮𝟵𝟬 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 (previously EUR 265 million) ▶️ 𝗘𝗕𝗜𝗧 𝗯𝗲𝗳𝗼𝗿𝗲 𝘀𝗽𝗲𝗰𝗶𝗮𝗹 𝗶𝘁𝗲𝗺𝘀: Now anticipated at ~𝗘𝗨𝗥 𝟲𝟬 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 (previously EUR 55 million) 𝗧𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 to our 𝘁𝗲𝗮𝗺𝘀, 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀, 𝗮𝗻𝗱 𝗰𝘂𝘀𝘁𝗼𝗺𝗲𝗿𝘀 who drive our success in 𝗮𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗻𝘂𝗰𝗹𝗲𝗮𝗿 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 and radiopharmaceutical innovation. Together, we're building the 𝗳𝘂𝘁𝘂𝗿𝗲 for patients and medical professionals worldwide. 💙 #Investors #FY2024  #NuclearMedicine #Radiopharmaceuticals #ContributingToSavingLives  

𝗦𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁𝗶𝗻𝗴 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 at the Jefferies 𝗟𝗼𝗻𝗱𝗼𝗻 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝟮𝟬𝟮𝟰! 🚀 Yesterday, our CEO Dr. Harald Hasselmann had the honor of representing Eckert & Ziegler at the 15th anniversary of the 𝗹𝗮𝗿𝗴𝗲𝘀𝘁 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲-𝗱𝗲𝗱𝗶𝗰𝗮𝘁𝗲𝗱 𝗰𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 in Europe, the Jefferies London Healthcare Conference. 🙌 The event brought together 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗹𝗲𝗮𝗱𝗲𝗿𝘀 𝗮𝗻𝗱 𝗶𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗶𝗼𝗻𝗮𝗹 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀 to explore the 𝗰𝘂𝗿𝗿𝗲𝗻𝘁 𝘁𝗿𝗲𝗻𝗱𝘀 shaping global healthcare and discuss both near- and long-term 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀. 📈 For Eckert & Ziegler, the 𝗽𝗮𝗰𝗸𝗲𝗱 𝘀𝗰𝗵𝗲𝗱𝘂𝗹𝗲 𝗼𝗳 𝟭-𝗼𝗻-𝟭 𝗺𝗲𝗲𝘁𝗶𝗻𝗴𝘀 offered a unique platform to 𝘀𝗵𝗼𝘄𝗰𝗮𝘀𝗲 how our innovations are 𝗱𝗿𝗶𝘃𝗶𝗻𝗴 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀 in the fields of 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀, 𝗻𝘂𝗰𝗹𝗲𝗮𝗿 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲, and beyond. These exchanges pave the way for 𝗶𝗺𝗽𝗮𝗰𝘁𝗳𝘂𝗹 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻𝘀 and further solidify our position as a 𝗹𝗲𝗮𝗱𝗲𝗿 𝗶𝗻 𝘁𝗵𝗲 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆. 🏆 We’re happy to be part of this 𝗱𝘆𝗻𝗮𝗺𝗶𝗰 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝘁𝘆 and look forward to continuing the dialogue that 𝗱𝗿𝗶𝘃𝗲𝘀 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗺𝗲𝗻𝘁𝘀 𝗶𝗻 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲. 🏥 #JefferiesHealthcare #Investors  #NuclearMedicine #Radiopharmaceuticals #ContributingToSavingLives